Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon Pharma Limited, a wholly-owned subsidiary of Biocon, has received U.S. FDA approval for its ANDA for Liraglutide Injection (generic Victoza), 18 mg/3 mL prefilled pens, used to treat Type 2 Diabetes in adults and children aged 10+. This is the second Liraglutide approval for the company in recent weeks, following the approval for generic Saxenda on February 24, 2026. Liraglutide is a complex GLP-1 class drug, and the approval strengthens Biocon's portfolio of complex generic products for the U.S. market. Victoza is a blockbuster product originally developed by Novo Nordisk, and generic entry typically opens a sizeable revenue opportunity for approved manufacturers.
Positive for shareholders — the U.S. FDA nod allows Biocon Pharma to launch a generic version of a high-value diabetes drug in the lucrative U.S. market, which could translate into meaningful new revenue. Back-to-back Liraglutide approvals signal strengthening execution in complex generics and may support long-term growth visibility.